8-K/A: Turnstone Biologics Finalizes Executive Departures and Transition Agreements

Turnstone Biologics Corp. has formally executed separation and consulting agreements with its Chief Executive Officer and Chief Operating Officer, detailing severance packages and transitional consulting roles.

Summary

• Turnstone Biologics Corp. filed an Amendment No. 2 to its Form 8-K to report the formal entry into separation and consulting agreements with its Chief Executive Officer, Sammy Farah, M.B.A., Ph.D., and Chief Operating Officer, Saryah Azmat.
• Sammy Farah's employment terminated on July 31, 2025, and he will receive a severance payment of $618,700.00, a bonus severance of $68,057.00, and a COBRA equivalent payment of $33,264.60.
• Sammy Farah is eligible for an additional cash payment of $148,874.69 contingent upon the successful closing of a contemplated merger transaction involving XOMA Royalty Corporation.
• Sammy Farah will serve as a consultant to the Company from August 1, 2025, until December 31, 2025, at a rate of $500.00 per hour, for up to 10 hours per week, assisting with potential transaction matters.
• Saryah Azmat's employment terminated on June 30, 2025, and she will receive a severance payment of $320,175.00, a bonus severance of $34,152.00, and a COBRA equivalent payment of $8,218.49.
• Saryah Azmat is eligible for an additional cash payment of $64,035.00 contingent upon the successful closing of the same contemplated merger transaction.
• Saryah Azmat will serve as a Business Development and Operational Consultant from July 1, 2025, until December 31, 2025, at a rate of $425.00 per hour, for up to 10 hours per week, supporting closing and transition items related to Iovance, Moffitt (including IP transfer), and XOMA transactions.
• Both executives will receive outplacement services up to $5,000.00 and are subject to confidentiality, non-disparagement, and cooperation clauses.

Sentiment

Score: 4

Explanation: The departure of key executives (CEO and COO) is a significant event, but the structured separation with consulting roles and contingent payments tied to a potential merger suggests a planned transition rather than an abrupt crisis. However, the substantial severance costs and the inherent uncertainty of leadership changes and contingent transactions weigh negatively, leading to a slightly negative to neutral sentiment.

Positives

• The company has secured consulting services from its departing CEO and COO to ensure a structured transition and assistance with ongoing strategic transactions until December 31, 2025.
• The separation agreements include clauses for confidentiality, non-disparagement, and cooperation, which are beneficial for the company's ongoing operations and reputation.
• Outplacement services are provided to the departing executives, which can facilitate a smoother transition for them.

Negatives

• The departure of both the Chief Executive Officer and Chief Operating Officer represents a significant change in top leadership, which could introduce uncertainty.
• The company will incur substantial severance costs totaling $938,875.00 (excluding contingent payments and consulting fees) for the two executives.
• Vesting of stock options for both executives ceased as of their respective separation dates, potentially impacting executive retention or motivation prior to separation.

Risks

• Potential disruption to ongoing operations and strategic initiatives due to the departure of key leadership personnel.
• Reliance on former executives as consultants for critical transaction matters, which could pose risks if their availability or performance is not as expected.
• Financial burden from severance packages and ongoing consulting fees, impacting the company's cash flow.
• Uncertainty surrounding the successful closing of the anticipated merger, which affects the contingent additional payments to the executives and the broader strategic direction.

Future Outlook

The company anticipates entering into a potential merger or series of transactions with XOMA Royalty Corporation, which will trigger additional cash payments to the departing executives upon successful closing. Consulting services from the former CEO and COO are secured until December 31, 2025, to assist with these potential transaction matters and other closing and transition items related to Iovance, Moffitt (including IP transfer), and XOMA transactions.

Management Comments

• The Compensation Committee of the Company's Board of Directors approved Separation and Consulting Agreements with Sammy Farah and Saryah Azmat on June 26, 2025.
• The company is filing this Amendment No. 2 solely to report the entry on July 11, 2025, into the Azmat Separation Agreement and entry on July 17, 2025, into the Farah Separation Agreement.

Industry Context

The executive transitions at Turnstone Biologics, coupled with the mention of a potential merger with XOMA Royalty Corporation and ongoing transactions related to Iovance and Moffitt, suggest a significant strategic realignment within the biotechnology sector. Such changes are common in the industry, particularly for companies undergoing M&A activities or restructuring their R&D focus, aiming to optimize operations or integrate new assets.

Management Changes

Stakeholder Impact

• Shareholders: May experience uncertainty due to leadership changes and the financial impact of severance costs, but also potential benefits from a successful merger and strategic realignment.
• Employees: May face changes in leadership and organizational structure, potentially impacting morale or future roles.
• Customers/Suppliers: Unlikely to be directly impacted in the short term, but long-term relationships could be influenced by new leadership and strategic direction.
• Creditors: Financial obligations related to severance payments could impact short-term liquidity, but the overall financial health and strategic direction (e.g., merger) would be more significant.

Next Steps

• Successful closing of the anticipated merger or series of transactions with XOMA Royalty Corporation.
• Payment of additional contingent cash payments to Sammy Farah and Saryah Azmat within thirty (30) days after the closing date of the merger, if earned.
• Sammy Farah and Saryah Azmat to provide consulting services to the company until December 31, 2025, assisting with transaction matters and operational transitions.

Key Dates

Recommendation

Keywords

Turnstone Biologics, SEC filing, 8-K/A, executive separation, CEO departure, COO departure, severance agreement, consulting agreement, corporate governance, management change, biotechnology, XOMA Royalty Corporation, merger, biopharma